We are pulmonary hypertension (PH) professionals united in our vision for a world without pulmonary vascular disease (PVD). We believe we can achieve this together, and we won’t stop until we do.
PVRI 2026 Fundraising events
Join us for two optional fundraising activities at PVRI 2026 Dublin as we celebrate 20 years of global collaboration. Take part in our morning run/walk or relaxed pub social and help support PVRI’s mission to advance PH awareness, research, and care worldwide.
Our PVRI Digital Webinar Series alternates between 'Cutting Edge Innovation in Clinical & Experimental PH' and 'Living Legends in PH: History & Personal Perspectives' sessions. Don't miss out!
This November, we’re coming together as one global team to shine a light on PH research and innovation during PH Awareness month through our new fundraising challenge: Breath Beyond Borders. PVRI friends across the world are taking on a personal challenge that pushes their limits. Find out how you can get involved.
Leading researchers showcase cutting-edge bioengineering and bioprinting technologies — from organ-on-a-chip models to 3D-printed vasculature — driving new insights into pulmonary hypertension mechanisms and therapies.
Living Legend Stuart Rich shares insights from four decades of pioneering research that transformed the understanding and treatment of pulmonary hypertension, in conversation with Serpil Erzurum and Saad Kubba.
This webinar brings together leading experts to explore the urgent need for new therapies in bronchopulmonary dysplasia-associated pulmonary hypertension. You’ll gain a clear overview of current care, key research gaps, and the real-world challenges of designing meaningful trials for preterm infants — all aimed at advancing treatment for this under-recognised condition.
Schistosomiasis and sickle cell disease (SCD) both cause pulmonary hypertension (PH). We identified a subject with sickle cell trait and hepatosplenic schistosomiasis, who on right heart catheterization had PH, but due to high cardiac output. In a pre-clinical model, we found SCD mice were protected from developing schistosomiasis-induced PH.
In patients with pulmonary arterial hypertension (PAH), limited real-world data are available on persistence to oral treprostinil therapy, particularly while transitioning from parenteral prostacyclins.
An on-demand recording of PVRI’s December PH Community Call, featuring informal discussion on emerging science and patient-focused research in pulmonary hypertension. The session covers new insights into hypoxic PH mechanisms and exercise interventions in PAH, with expert-led moderation and open exchange.
These annual awards are given in recognition of outstanding contributions to the field of pulmonary hypertension. They celebrate notable achievements made by special individuals across the world. The PVRI Lifetime Achievement Award 2025, the PVRI Achievement Awards 2025 and the PVRI Special Recognition Award will be presented at PVRI 2026 Dublin.
We’re excited to announce the relaunch of the PVRI Digital Webinar Series, beginning September 2025. This free monthly series, open to all, brings together the global PH community for keynote presentations, rich discussion, and the opportunity to learn cutting-edge new research.
This PH Awareness Month, we’re inviting you to join the global PVRI community for our very first Breath Beyond Borders challenge. Throughout November, PVRI members and friends around the world will be taking on personal challenges — walking, running, cycling, speed skating, or even playing the piano — to shine a light on PH research and innovation, and raise funds for PVRI along the way.
